Table 1 Baseline characteristics
Characteristic | Sugammadex (n = 59) | Neostigmine (n = 61) |
|---|---|---|
Age (years) | 64.6 (11.1) | 62.7 (10.1) |
Sex | ||
 Male | 33 (55.9) | 37 (60.7) |
 Female | 26 (44.1) | 24 (39.3) |
Body mass index (kg/m2) | 25.6 (4.6) | 27.0 (5.8) |
ASA physical status | ||
 1 | 1 (1.7) | 5 (8.2) |
 2 | 35 (59.3) | 33 (54.1) |
 3 | 22 (37.3) | 22 (36.1) |
 4 | 1 (1.7) | 1 (1.6) |
History of PONV or motion sickness | 13 (22.0) | 5 (8.2) |
Apfel simplified risk score | ||
 1 | 3 (5.1) | 6 (9.8) |
 2 | 28 (47.5) | 31 (50.8) |
 3 | 18 (30.5) | 21 (34.4) |
 4 | 10 (16.9) | 3 (4.9) |
ARISCAT score | 38 (26–42) | 34 (26–41) |
ARISCAT risk | ||
 Low (<26) | 16 (27.1) | 20 (32.8) |
 Intermediate (26–44) | 29 (49.2) | 34 (55.7) |
 High (>44) | 14 (23.7) | 7 (11.5) |
QoR-15 score | 136.0 (123.0–144.0) | 141.0 (132.0–144.0) |
EQ-5D-5L score | 0.9 (0.8–1.0) | 0.9 (0.9–1.0) |
EQ-VAS score | 80.0 (75.0–90.0) | 80.0 (75.0–90.0) |
Frailty | ||
 Non-frail (CFS score 1–4) | 57 (96.6) | 59 (96.7) |
 Frail (CFS score 5–9) | 2 (3.4) | 2 (3.3) |